{"transactions":[{"id":896813,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":65899,"kind":"person","name":"Piper Brian","position":1,"cik":"0001665924","reported_name":"Piper Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-18T16:35:39.000Z","date":"2026-02-17","kind":"grant","planned":false,"acquired":true,"shares":900000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests and becomes exercisable as to 25% of the underlying shares on February 17, 2027 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date."}],"balance_after":900000,"derivative":{"exercise_price":3.85,"expiration_date":"2036-02-16","underlying":"Common Stock","underlying_shares":900000},"source":{"system":"sec-edgar","filing":"0001665924-26-000008","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1665924/000166592426000008/primarydocument.xml","form_type":"4"}},{"id":896812,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":65899,"kind":"person","name":"Piper Brian","position":1,"cik":"0001665924","reported_name":"Piper Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-02-18T16:35:39.000Z","date":"2026-02-17","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. (\"Sana\") common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vest in four equal installments on each of February 17, 2027, 2028, 2029 and 2030, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vest in four equal installments on each of February 17, 2027, 2028, 2029 and 2030, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date."}],"balance_after":200000,"derivative":{"underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001665924-26-000008","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1665924/000166592426000008/primarydocument.xml","form_type":"4"}},{"id":2588175,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":65899,"kind":"person","name":"Piper Brian","position":1,"cik":"0001665924","reported_name":"Piper Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-08-27T20:02:38.000Z","date":"2021-08-25","kind":"exercise","acquired":false,"shares":8333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vested as to 25% of the total shares monthly beginning on July 1, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date."}],"balance_after":264329,"derivative":{"exercise_price":1.89,"expiration_date":"2029-08-06","underlying":"Common Stock","underlying_shares":8333},"source":{"system":"sec-edgar","filing":"0001209191-21-053758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1665924/000120919121053758/doc4.xml","form_type":"4"}},{"id":2588174,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":65899,"kind":"person","name":"Piper Brian","position":1,"cik":"0001665924","reported_name":"Piper Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-08-27T20:02:38.000Z","date":"2021-08-25","kind":"sale","acquired":false,"shares":2344,"price":34.3299,"value":80469.2856,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.82 to $34.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-053758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1665924/000120919121053758/doc4.xml","form_type":"4"}},{"id":2588173,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":65899,"kind":"person","name":"Piper Brian","position":1,"cik":"0001665924","reported_name":"Piper Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-08-27T20:02:38.000Z","date":"2021-08-25","kind":"sale","acquired":false,"shares":3889,"price":33.2308,"value":129234.5812,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.78 to $33.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":2344,"source":{"system":"sec-edgar","filing":"0001209191-21-053758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1665924/000120919121053758/doc4.xml","form_type":"4"}},{"id":2588172,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":65899,"kind":"person","name":"Piper Brian","position":1,"cik":"0001665924","reported_name":"Piper Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-08-27T20:02:38.000Z","date":"2021-08-25","kind":"sale","acquired":false,"shares":2100,"price":32.4398,"value":68123.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.77 to $32.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":6233,"source":{"system":"sec-edgar","filing":"0001209191-21-053758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1665924/000120919121053758/doc4.xml","form_type":"4"}},{"id":2588171,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":65899,"kind":"person","name":"Piper Brian","position":1,"cik":"0001665924","reported_name":"Piper Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-08-27T20:02:38.000Z","date":"2021-08-25","kind":"exercise","acquired":true,"shares":8333,"price":1.89,"value":15749.37,"ownership":{"direct":true},"balance_after":8333,"source":{"system":"sec-edgar","filing":"0001209191-21-053758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1665924/000120919121053758/doc4.xml","form_type":"4"}},{"id":2627165,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":65899,"kind":"person","name":"Piper Brian","position":1,"cik":"0001665924","reported_name":"Piper Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-07-22T18:09:32.000Z","date":"2021-07-20","kind":"grant","acquired":true,"shares":115650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 25% of the total shares on July 20, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":115650,"derivative":{"exercise_price":31.23,"expiration_date":"2031-07-19","underlying":"Common Stock","underlying_shares":115650},"source":{"system":"sec-edgar","filing":"0001209191-21-047835","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1665924/000120919121047835/doc4.xml","form_type":"4"}},{"id":2693384,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":65899,"kind":"person","name":"Piper Brian","position":1,"cik":"0001665924","reported_name":"Piper Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-05-27T17:03:20.000Z","date":"2021-05-25","kind":"exercise","acquired":false,"shares":8333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option vested as to 25% of the total shares monthly beginning on July 1, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date."}],"balance_after":272662,"derivative":{"exercise_price":1.89,"expiration_date":"2029-08-06","underlying":"Common Stock","underlying_shares":8333},"source":{"system":"sec-edgar","filing":"0001209191-21-036297","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1665924/000120919121036297/doc4.xml","form_type":"4"}},{"id":2693383,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":65899,"kind":"person","name":"Piper Brian","position":1,"cik":"0001665924","reported_name":"Piper Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-05-27T17:03:20.000Z","date":"2021-05-25","kind":"sale","acquired":false,"shares":399,"price":36.093,"value":14401.107,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.92 to $36.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-036297","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1665924/000120919121036297/doc4.xml","form_type":"4"}},{"id":2693382,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":65899,"kind":"person","name":"Piper Brian","position":1,"cik":"0001665924","reported_name":"Piper Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-05-27T17:03:20.000Z","date":"2021-05-25","kind":"sale","acquired":false,"shares":1736,"price":35.4469,"value":61535.8184,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.91 to $35.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":399,"source":{"system":"sec-edgar","filing":"0001209191-21-036297","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1665924/000120919121036297/doc4.xml","form_type":"4"}},{"id":2693381,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":65899,"kind":"person","name":"Piper Brian","position":1,"cik":"0001665924","reported_name":"Piper Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-05-27T17:03:20.000Z","date":"2021-05-25","kind":"sale","acquired":false,"shares":3088,"price":34.1119,"value":105337.5472,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.83 to $34.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":2135,"source":{"system":"sec-edgar","filing":"0001209191-21-036297","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1665924/000120919121036297/doc4.xml","form_type":"4"}},{"id":2693380,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":65899,"kind":"person","name":"Piper Brian","position":1,"cik":"0001665924","reported_name":"Piper Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-05-27T17:03:20.000Z","date":"2021-05-25","kind":"sale","acquired":false,"shares":3110,"price":33.525,"value":104262.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.83 to $33.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":5223,"source":{"system":"sec-edgar","filing":"0001209191-21-036297","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1665924/000120919121036297/doc4.xml","form_type":"4"}},{"id":2693379,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":65899,"kind":"person","name":"Piper Brian","position":1,"cik":"0001665924","reported_name":"Piper Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-05-27T17:03:20.000Z","date":"2021-05-25","kind":"exercise","acquired":true,"shares":8333,"price":1.89,"value":15749.37,"ownership":{"direct":true},"balance_after":8333,"source":{"system":"sec-edgar","filing":"0001209191-21-036297","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1665924/000120919121036297/doc4.xml","form_type":"4"}},{"id":3890955,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":65899,"kind":"person","name":"Piper Brian","position":1,"cik":"0001665924","reported_name":"Piper Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Corporate Secretary"}}],"security":"Stock Option (Right to Purchase)","published_at":"2018-06-18T16:25:31.000Z","date":"2018-06-14","kind":"grant","acquired":true,"shares":238000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option award was granted on April 17, 2018 and was subject to forfeiture if stockholder approval of a proposed amendment to the Issuer's stock incentive plan to increase the number of shares reserved for issuance under the plan was not obtained. The Issuer's stockholders approved the amendment to the Issuer's stock incentive plan at the Issuer's annual meeting of stockholders on June 14, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option award vests and becomes exercisable as follows (rounded up to the nearest whole share of common stock): one-third on April 17, 2019, then in 24 equal monthly installments on the 17th day of each subsequent calendar month, subject to the reporting person's continued service with the issuer."}],"balance_after":238000,"derivative":{"exercise_price":1.55,"expiration_date":"2028-04-17","underlying":"Common Stock","underlying_shares":238000},"source":{"system":"sec-edgar","filing":"0001192482-18-000302","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000119248218000302/edgar.xml","form_type":"4"}},{"id":3931159,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":65899,"kind":"person","name":"Piper Brian","position":1,"cik":"0001665924","reported_name":"Piper Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Corporate Secretary"}}],"security":"Stock Option (Right to Purchase)","published_at":"2018-05-16T16:37:45.000Z","date":"2018-05-14","kind":"grant","acquired":true,"shares":270000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award vests and becomes exercisable as follows (rounded up to the nearest whole share of common stock): one-third on May 14, 2019, then in 24 equal monthly installments on the 14th day of each subsequent calendar month, subject to the reporting person's continued service with the issuer."}],"balance_after":270000,"derivative":{"exercise_price":1.51,"expiration_date":"2028-05-14","underlying":"Common Stock","underlying_shares":270000},"source":{"system":"sec-edgar","filing":"0001192482-18-000225","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000119248218000225/edgar.xml","form_type":"4"}},{"id":3931158,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":65899,"kind":"person","name":"Piper Brian","position":1,"cik":"0001665924","reported_name":"Piper Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Corporate Secretary"}}],"security":"Stock Option (Right to Purchase)","published_at":"2018-05-16T16:36:09.000Z","date":"2017-08-11","kind":"grant","acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Reflects a reduction in the number of shares purchaseable under the stock option.  A portion of the originally granted amount was void due to having exceeded certain plan limitations."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award vests and becomes exercisable as follows (rounded up to the nearest whole share of common stock): one-third on August 11, 2018, then in 24 equal monthly installments on the 11th day of each subsequent calendar month, subject to the reporting person's continued service with the issuer."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Reflects a reduction in the number of shares purchaseable under the stock option.  A portion of the originally granted amount was void due to having exceeded certain plan limitations."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects a reduction in the number of shares purchaseable under the stock option.  A portion of the originally granted amount was void due to having exceeded certain plan limitations."}],"balance_after":110000,"derivative":{"exercise_price":1.32,"expiration_date":"2027-08-11","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001192482-18-000224","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000119248218000224/edgar.xml","form_type":"4/A","original_submission_date":"2017-08-15"}},{"id":4234124,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":65899,"kind":"person","name":"Piper Brian","position":1,"cik":"0001665924","reported_name":"Piper Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Corporate Secretary"}}],"security":"Stock Option (Right to Purchase)","published_at":"2017-08-15T16:17:10.000Z","date":"2017-08-11","kind":"grant","acquired":true,"shares":380000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award vests and becomes exercisable as follows (rounded up to the nearest whole share of common stock): one-third on August 11, 2018, then in 24 equal monthly installments on the 11th day of each subsequent calendar month, subject to the reporting person's continued service with the issuer."}],"balance_after":380000,"derivative":{"exercise_price":1.32,"expiration_date":"2027-08-11","underlying":"Common Stock","underlying_shares":380000},"source":{"system":"sec-edgar","filing":"0001144204-17-043513","document":"v473387_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000114420417043513/v473387_form4.xml","form_type":"4"}},{"id":4439786,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":65899,"kind":"person","name":"Piper Brian","position":1,"cik":"0001665924","reported_name":"Piper Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Purchase)","published_at":"2017-02-17T17:43:34.000Z","date":"2017-02-17","kind":"grant","acquired":true,"shares":190000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award vests and becomes exercisable in three equal installments (rounded up to the nearest whole share of common stock) on February 17, 2018, February 17, 2019 and February 17, 2020, subject to the reporting person's continued service with the issuer."}],"balance_after":190000,"derivative":{"exercise_price":4.91,"expiration_date":"2027-02-17","underlying":"Common Stock","underlying_shares":190000},"source":{"system":"sec-edgar","filing":"0001192482-17-000046","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000119248217000046/edgar.xml","form_type":"4"}}]}